Treats acute symptomatic hypocalcemia. Sold as Calcium Chloride 10% In Plastic Container. Every FDA application for this active ingredient: 1 branded and 7 generic.
As of Nov 15, 2026, FDA lists 8 applications for Calcium Chloride (sold as Calcium Chloride 10% In Plastic Container), first approved Jan 28, 2000, with 0 new uses approved and 0 published complete response letters.
| Platelet-Rich Plasma for Bone Healing in Maxillary and Mandibular FracturesMandibular Fractures, Maxillary Fractures · CMH Lahore Medical College and Institute of Dentistry | Not applicable | Recruiting | Nov 10, 2026 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · City of Hope Medical Center | Phase 1 | Not yet recruiting | Nov 3, 2026 |
| Spirulina Gel in the Treatment of PeriodontitisPeriodontitis, Periodontitis Stage II · Misr University for Science and Technology | Not applicable | Not yet recruiting | Oct 26, 2026 |
| Strategy for Managing Urinary Incontinence With PRPUrinary Incontinence, Platelet Rich Plasma · GCS Ramsay Santé pour l'Enseignement et la Recherche | Not applicable | Not yet recruiting | Sep 22, 2026 |
| Meniscal Repair Augmented With Leukocyte-Poor Platelet-Rich Plasma: A Prospective Comparative Clinical StudyMeniscal Tears · Universidad Autonoma de Nuevo Leon | Not applicable | Not yet recruiting | Sep 11, 2026 |
| FiLaC and PRGF-Endoret for Multi-recurrent Cryptoglandular Perianal Fistula (PLASMA Pilot Study)Perianal Fistula · Complejo Hospitalario Universitario de Santiago | Not applicable | Not yet recruiting | Sep 9, 2026 |
| Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)Breast Cancer, Lipofilling · The Leningrad Regional Clinical Hospital | Not applicable | Recruiting | Jun 18, 2026 |
| Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationSevere High Altitude Pulmonary Edema, Severe High Altitude Cerebral Edema · Tibet Autonomous Region People's Hospital | Not applicable | Not yet recruiting | Jun 10, 2026 |
| Jan 28, 2000 | Calcium Chloride 10% In Plastic ContainerNDA 21117 · New dosage form | Hospira | 5 | Marketed |
| Jul 27, 2017 | Calcium Chloride 10%ANDA 209088 | Am Regent | 0 | Marketed |
| May 9, 2018 | Calcium Chloride 10%ANDA 203477 | Intl Medication Sys | 1 | Marketed |
| May 1, 2019 | Calcium Chloride 10%ANDA 211553 | Medefil Inc | 0 | Marketed |
| Jul 8, 2024 | Calcium Chloride 10%ANDA 217524 | Amneal | 1 | Marketed |
| Nov 27, 2024 | Calcium Chloride 10%ANDA 219342 | Pharmazone | 0 | Marketed |
| Dec 17, 2024 | Calcium Chloride 10%ANDA 218133 | Somerset | 0 | Marketed |
| Sep 29, 2025 | Calcium Chloride 10%ANDA 217463 | Square Pharms PLC | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
